Abingdon Health PLC Exercise of Options and TVR (3037M)

TIDMABDX

RNS Number : 3037M

Abingdon Health PLC

20 May 2022

Abingdon Health plc

("Abingdon" or the "Company")

Exercise of Options and Total Voting Rights

York, U.K. 20 May 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that it has applied for 12,500 new ordinary shares of 0.025 pence each ("Ordinary Shares") in the Company to be admitted to trading on AIM on 25 May 2022 following an exercise of share options.

Following the issue of the 12,500 new Ordinary Shares the Company will have a total of 121,711,614 Ordinary Shares in issue. The Company does not hold any shares in Treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
 Abingdon Health plc                                  www.abingdonhealth.com/investors/ 
 Chris Yates, Chief Executive Officer                                   Via Walbrook PR 
 Melanie Ross , Chief Financial Officer 
 Dr Chris Hand, Non-Executive Chairman 
 
 Singer Capital Markets (Sole Broker and                       Tel: [phone] 
  Nominated Adviser) 
 Peter Steel, Alex Bond, Sam Butcher (Corporate 
  Finance) 
 Tom Salvesen (Corporate Broking) 
 
 Walbrook PR Limited                Tel: [phone] or [e-mail] 
 Paul McManus / Phillip                      Mob: [phone] 
  Marriage                                                                          082 
 Alice Woodings                                                Mob: [phone] 
 
 

About Abingdon Health plc

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx(R) , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEDZGZKMGRGZZM

(END) Dow Jones Newswires

May 20, 2022 07:51 ET (11:51 GMT)